CN117126949A - Cell type and traceability method for identifying primary cells in amniotic fluid sample - Google Patents
Cell type and traceability method for identifying primary cells in amniotic fluid sample Download PDFInfo
- Publication number
- CN117126949A CN117126949A CN202311398690.6A CN202311398690A CN117126949A CN 117126949 A CN117126949 A CN 117126949A CN 202311398690 A CN202311398690 A CN 202311398690A CN 117126949 A CN117126949 A CN 117126949A
- Authority
- CN
- China
- Prior art keywords
- cells
- cell
- amniotic fluid
- cluster
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004381 amniotic fluid Anatomy 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title claims abstract description 31
- 230000001605 fetal effect Effects 0.000 claims abstract description 35
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 35
- 230000014509 gene expression Effects 0.000 claims abstract description 29
- 210000000056 organ Anatomy 0.000 claims abstract description 18
- 210000001654 germ layer Anatomy 0.000 claims abstract description 14
- 238000012163 sequencing technique Methods 0.000 claims abstract description 13
- 238000007621 cluster analysis Methods 0.000 claims abstract description 6
- 210000003754 fetus Anatomy 0.000 claims description 16
- 238000012216 screening Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 230000035935 pregnancy Effects 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000002771 cell marker Substances 0.000 claims description 2
- 238000010839 reverse transcription Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 161
- 210000004556 brain Anatomy 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 210000000274 microglia Anatomy 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- 102100021633 Cathepsin B Human genes 0.000 description 2
- 102100025849 Complement C1q subcomponent subunit C Human genes 0.000 description 2
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 2
- 101000898449 Homo sapiens Cathepsin B Proteins 0.000 description 2
- 101000933636 Homo sapiens Complement C1q subcomponent subunit C Proteins 0.000 description 2
- 101000746364 Homo sapiens Granulocyte colony-stimulating factor receptor Proteins 0.000 description 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 2
- 210000002556 adrenal cortex cell Anatomy 0.000 description 2
- 210000001691 amnion Anatomy 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000006360 Edwards syndrome Diseases 0.000 description 1
- 206010052096 Hydrometra Diseases 0.000 description 1
- 238000012351 Integrated analysis Methods 0.000 description 1
- 101100261006 Salmonella typhi topB gene Proteins 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012174 single-cell RNA sequencing Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 101150032437 top-3 gene Proteins 0.000 description 1
- 206010053884 trisomy 18 Diseases 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 230000002620 ureteric effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a method for identifying the cell type and tracing the primary cells in amniotic fluid samples, which is characterized by comprising the following steps: s1, capturing single cells in primary cells in a amniotic fluid sample, and sequencing to obtain data of the amniotic fluid sample; s2, fetal cell data are obtained; s3, grouping cells and carrying out cluster analysis; s4, carrying out high expression gene identity identification on the group without fetal cell distribution; s5, identifying the amniotic fluid cells and annotating organ sources and germ layers. The invention not only performs cell tracing aiming at amniotic fluid samples, but also explains the organ sources and germ layer sources of amniotic fluid cells, so that the classification and tracing of cells are more accurate.
Description
Technical Field
The invention relates to the field of medicine, in particular to a method for identifying cell types and tracing primary cells in amniotic fluid samples.
Background
Amniotic sac is a pair of tough but thin transparent membranes, the outer membrane is also called chorion, which surrounds the amniotic membrane, which is part of the placenta, and the inner membrane, i.e., the amniotic membrane, surrounds amniotic fluid and fetus. The initial amniotic fluid is isotonic, contains carbohydrates, proteins, phospholipids, lipids, urea, electrolytes, and the like, and changes its composition as urine discharged from the fetus increases. The amniotic fluid can keep consistent pressure and temperature, plays a role in buffering and protecting embryos, can allow the fetus to freely move in uterus, is beneficial to the musculoskeletal development and blood flow of the fetus, and in addition, the fetus can inhale the amniotic fluid to promote the normal growth and development of the lung, and the fetus can swallow the amniotic fluid in uterus to be beneficial to the development of the gastrointestinal tract. Amniotic fluid is 207+/-92 ml at 6 weeks of pregnancy, 258+/-97 ml at 18 weeks and 365+/-88 ml at 20 weeks, and the number of amniotic fluid cells is relatively heterogeneous, the number of cells in amniotic fluid in the middle of pregnancy varies between 10 and 1000 cells/μl, and most researches consider that amniotic fluid cells are composed of various fetal tissue shedding cells in contact with amniotic fluid, but the cell types of amniotic fluid cells and the number ratio of various cell types are still unknown.
At present, single-Cell Transcriptomics of Cultured Amniotic Fluid Cells Reveals Complex Gene Expression Alterations in Human Fetuses With Trisomy 18 collects cultured second-generation amniotic fluid cell samples, then Single-cell transcriptome sequencing is carried out by using a 10xGenomics Single-cell capturing and sequencing technology, after dimension-reduction clustering analysis is carried out on data by using t-SNE, the differential expression genes of cells in a specific group (Cluster) and all other groups (Cluster) of cells are determined by using Wilcox in a SEurat package, and then the differential expression genes of cells in the specific group (Cluster) and cells in each other group (Cluster) are determined by using a DESeq2 package. However, this method did not conduct studies of lineage and germ layer traceability, but classified amniotic cells into 6 major classes according to functional analysis.
The scRNA-Seq of Cultured Human Amniotic Fluid from Fetuses with Spina Bifida Reveals the Origin and Heterogeneity of the Cellular Content is characterized in that amniotic fluid cells are firstly subjected to in vitro culture and adherence for 5 days, namely P0 generation cells are collected, then single cell transcriptome sequencing is carried out by using a 10xGenomics single cell capturing and sequencing technology, data are subjected to dimension reduction clustering analysis by using t-SNE, the average expression difference between cells in a test group (Cluster) and the rest cells is at least 0.25 times (logarithmic scale), the genes with P value less than 0.05 after adjustment are identified as differential expression genes, and then enrichment analysis is carried out by using an R packet profiler, namely the differential expression genes of each group (Cluster) are selected and analyzed according to biological processes in Gene Ontolog as categories. Finally, the study identified 4 tissue sources of amniotic fluid cells by high expression genes, and then identified different cell types of the same tissue sources by high expression genes, however, no analysis of germ layer sources was performed in the method, and the sources of the cells were not known.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a method for identifying the cell type and tracing the primary cells in the amniotic fluid sample, and the method is used for identifying the cell identity of the primary cells without culturing the cells in the process of identifying the cell identity, so that the cell screening caused by the culturing process is avoided, the change of the cell type or the cell number in the culturing process is also avoided, and the analysis of the primary cells in the amniotic fluid sample is more accurate by classifying the amniotic fluid cells and identifying the cell identity through high-expression genes.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
a method for identifying the cell type and tracing of primary cells in amniotic fluid samples, comprising the steps of;
s1, capturing single cells in primary cells in a amniotic fluid sample, and sequencing to obtain data of the amniotic fluid sample;
s2, fetal cell data are obtained;
s3, grouping cells and carrying out cluster analysis;
s4, carrying out high expression gene identity identification on the group without fetal cell distribution;
s5, carrying out identification and annotation of organ sources and germ layers sources on amniotic fluid cells.
Further, the specific steps of capturing single cells and sequencing in the step S1 are as follows: single cell capturing is completed through a single cell capturing platform; the mRNA is then captured for reverse transcription and library-building sequencing.
Further, the specific steps of obtaining fetal cell data in S2 are: and collecting gene expression matrixes of single-cell transcriptome data of the fetus, and cell type and organ source information of each cell.
Further, the gestational age of the fetus is close to the gestational week of the amniotic fluid sample to be analyzed.
Further, the specific steps of S3 cell grouping are as follows:
1) Respectively constructing a serum object from fetal cell data and amniotic fluid sample data, wherein the sample data and the fetal cell data are mapped;
2) Dividing the cells into different groups (clusters) by UMAP Cluster analysis;
3) The number of cells of different cell types of fetal data and amniotic fluid sample cells distributed in different groups (Cluster) was counted, and the most distributed fetal cell type in each group (Cluster) was identified as the cell type of that group (Cluster).
Further, the plurality of cell types obtained in the 3) can be identified, wherein the group with fetal cell distribution can be identified, and the group without fetal cell distribution can be identified by high expression genes.
Further, the specific steps of the identification of the S4 high expression gene are as follows:
1) Finding high expression genes in a group (Cluster) without fetal cell distribution by using FindAllMarker;
2) Screening high-expression genes of a group (Cluster) without fetal cell distribution, and setting filtering and screening conditions;
3) Cell identification was performed on highly expressed genes of a Cluster (Cluster) without fetal cell distribution using the CellMarker database.
Further, the specific steps of annotating the amniotic fluid cells with organ sources and germ layer sources in S5 are as follows: based on organ origin, germ layer origin was determined.
The invention also provides the application of the method in identifying the cell type and tracing of primary cells in amniotic fluid samples, wherein the application is for non-diagnosis and treatment purposes.
The invention has the beneficial effects that: the method of the invention carries out cell identity identification aiming at primary cells in amniotic fluid samples, and the cells are not cultured, thereby avoiding 'cell screening' caused by the culture process and avoiding the change of cell types or numbers in the culture process. According to the invention, fetal cell data are referred to for tracing amniotic fluid cells in similar gestational weeks, so that not only is the amniotic fluid cells derived from a fetus demonstrated, but also the amniotic fluid cells are sample information in similar gestational weeks, and the tracing of the amniotic fluid cells is more reliable. According to the invention, cell tracing is performed on the amniotic fluid sample, the organ source and the germ layer source of the amniotic fluid cells are described, and cell identity identification is performed on specific cell types through high expression genes, so that the classification and tracing of the cells are more accurate.
Drawings
The accompanying drawings are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate the invention and together with the embodiments of the invention, serve to explain the invention. In the drawings:
FIG. 1 is a schematic representation of the expression of fetal cells and amniotic fluid cells in different populations (Cluster);
FIG. 2 is a schematic representation of cell types of each Cluster;
FIG. 3 is a schematic diagram of amniotic fluid cell types and cell numbers.
Detailed Description
The scheme of the present invention will be explained below with reference to examples. It will be appreciated by those skilled in the art that the following examples are illustrative of the present invention and should not be construed as limiting the scope of the invention. The examples are not to be construed as limiting the specific techniques or conditions described in the literature in this field or as per the specifications of the product. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Example 1:
this example is a single cell in 8 mid-gestation amniotic fluid samples. The aim was to determine the identity of these single cells and thus explore the organ and germ layer origin of amniotic fluid cells, and a total of 30063 single cells were obtained from 8 amniotic fluid samples of this batch. The method for identifying the cell type and tracing the primary cells in the amniotic fluid sample comprises the following steps:
s1, single cell capture sequencing
By the BD Rhapsody platform, cells were first made into specific single cell suspensions, and single cells were randomly distributed in more than 200,000 microwells according to the limiting dilution method, thereby completing single cell capture. Magnetic beads were then added to capture mRNA and reverse transcribed, and pool sequencing was performed.
S2, selecting cell information of reference data
Single cell transcriptome data of mid-gestation (10-18 weeks) fetuses were selected and stored in the loom format. Firstly, collecting a gene expression matrix of cells and cell type and organ source information of each cell by using a loomR package, and taking 1:100 as a fixed interval, namely taking data information of 1 cell every 100 cells, taking data information of 40621 cells in total, and carrying out subsequent integrated analysis to obtain fetal cell data.
S3, cell grouping
The fetal cell data and the data of 8 amniotic fluid samples are respectively constructed into a serum object, wherein the 8 sample data are combined and then mapped with the fetal cell data, the cells are divided into 22 groups (clusters) through UMAP Cluster analysis (resolution=0.4), then the different cell types of the fetal data and the cell numbers of the amniotic fluid samples distributed in the different groups (clusters) are counted, the fetal cell type most distributed in each group (Cluster) is identified as the cell type of the group (Cluster), and 18 cell types are identified in total, as shown in figure 1.
Obtaining inhibitory neurons of the brain from group 0 (Cluster 0), the brain from group 1 (Cluster 1) and group 5 (Cluster 5), the brain from excitatory neurons, the cerebellum from group 3 (Cluster 3), the cerebellum from group 11 (Cluster 11), the cerebellum from group 2 (Cluster 2) and the adrenal cortical cells from group 4 (Cluster 4), the liver from group 6 (Cluster 6), the liver from group 9 (Cluster 9) and group 16 (Cluster 16), the pancreas from group 7 (Cluster 7), the lung from group 8 (Cluster 8), the lung from group 10 (Cluster 10), the different organ-derived vascular endothelial cells from group 13 (Cluster 11), the different organ-derived vascular endothelial cells from group 14 (Cluster 14), the different organ-derived stromal cells from group 15 (Cluster) and the liver from group 21, the liver from group 21 (Cluster) and the main brain from group 21, the liver from group 21 and the liver from group 21. While group 12 (Cluster 12) and group 18 (Cluster 18) still require specific high-expression genes for identification.
S4, carrying out identity authentication on the high-expression gene
The high expression genes in various groups (Cluster) are found by using a FindAllMark, then the found high expression genes in all groups (Cluster) are screened, the top50 is extracted, filtering screening conditions (avg_logFC > =2, pct.1> =0.4 and pct.2> =0.4) are set, the high expression genes in the visible group 18 (Cluster 18) are CSF3R, CXR2 and SELL, and then cell identity recognition is carried out on the high expression genes in the group 18 (Cluster 18) by using a CellMark database (http:// 117.50.127.228/CellMark/index.html), wherein CSF3R and CXR2 are high expressed in neutrophils and SELL are high expressed in the T cells, and the group 18 (Cluster 18) is the neutrophils. Since there is no high expression gene of the Cluster12 (Cluster 12) after filtering and screening, the high expression gene of the top3 of the Cluster12 (Cluster 12) found by the FindAllMarker is identified. The high expression genes of the group 12 (Cluster 12) are CD74, C1QC and CTSB, wherein the CD74 and the CTSB are highly expressed in microglia of the brain, the C1QC is expressed in medullary cells of the brain, and the group 12 (Cluster 12) is consistent with the group 19 (Cluster 19), namely microglia.
In summary, each cell group was annotated according to fetal database and high-expression genes, and as shown in fig. 2, 17 cell types were identified in total.
S5, amniotic fluid cell identity identification and organ source and germ layer annotation
Of the 17 cell types identified, amniotic fluid cells were predominantly distributed among 10 cell types (shown in fig. 3), with more widely distributed cell types being intestinal epithelial cells of the intestinal tract, adrenal cortex cells of the adrenal gland, ureteric bud cells of the kidney, and acinar cells of the pancreas. In addition, some amniotic fluid cells are derived from microglia of the brain, thymus cells of the thymus, vascular endothelial cells, neutrophils, bronchioles of the lung and epithelial cells of the alveoli, and interstitial cells. While according to the knowledge of the development of the embryo, the intestinal epithelium is mainly derived from the midgut part of the original gut, the adrenal glands and kidneys are derived from the mesoderm, and the pancreas is mainly derived from the foregut part of the original gut, i.e. amniotic fluid cells are mainly derived from cells of the endodermal and mesodermal layers. Some amniotic cells are microglia derived from nervous system, which develop from ectoderm, but have a small cell content.
By the method, 10 cell types are identified in the amniotic fluid in the batch, wherein the cell types with more amniotic fluid cell distribution are intestinal epithelial cells of intestinal tracts, adrenal cortex cells of adrenal glands, ureteral bud cells of kidneys and acinar cells of pancreas. The cells accounting for a large number are mostly derived from mesoderm and endoderm, and cells derived from ectoderm in amniotic fluid samples are microglial cells with less distribution.
The method of the invention carries out cell identity identification aiming at primary cells in amniotic fluid samples, and the cells are not cultured, thereby avoiding 'cell screening' caused by the culture process and avoiding the change of cell types or numbers in the culture process. According to the invention, the fetal cell data in the midgestation stage is referred to for tracing the amniotic fluid cells in the midgestation stage, so that not only is the demonstration that the amniotic fluid cells are derived from the fetus in the midgestation stage, but also the information is sample information in the midgestation stage, and the tracing of the amniotic fluid cells in the midgestation stage is more credible. According to the invention, cell tracing is performed on the amniotic fluid sample, the organ source and the germ layer source of the amniotic fluid cells are described, and cell identity identification is performed on specific cell types through high expression genes, so that the classification and tracing of the cells are more accurate.
While embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and not to be construed as limiting the invention, and that variations, modifications, alternatives and variations may be made to the above embodiments by one of ordinary skill in the art within the scope of the invention.
Claims (9)
1. A method for identifying the cell type and tracing of primary cells in amniotic fluid samples, comprising the steps of:
s1, capturing single cells in primary cells in a amniotic fluid sample, and sequencing to obtain data of the amniotic fluid sample;
s2, fetal cell data are obtained;
s3, grouping cells and carrying out cluster analysis;
s4, identifying the group without fetal cell distribution through high expression genes;
s5, carrying out identification and annotation of organ sources and germ layers sources on amniotic fluid cells.
2. The method of claim 1, wherein the specific steps of capturing single cells and sequencing in S1 are: single cell capturing is completed through a single cell capturing platform; the mRNA is then captured for reverse transcription and library-building sequencing.
3. The method of claim 1, wherein the step of obtaining fetal cell data in S2 comprises the steps of: and collecting gene expression matrixes of single-cell transcriptome data of the fetus, and cell type and organ source information of each cell.
4. The method of claim 3, wherein the gestational age of the fetus is about the week of gestation with the amniotic fluid sample to be analyzed.
5. The method of claim 1, wherein the step of S3 cell grouping is as follows:
1) Respectively constructing a serum object from fetal cell data and amniotic fluid sample data, wherein the sample data and the fetal cell data are mapped;
2) Dividing the cells into different groups (clusters) by UMAP Cluster analysis;
3) The number of cells of different cell types of fetal data and amniotic fluid sample cells distributed in different groups (Cluster) was counted, and the most distributed fetal cell type in each group (Cluster) was identified as the cell type of that group (Cluster).
6. The method of claim 5, wherein a plurality of cell types are obtained in 3), wherein the identification is performed with a population having fetal cell distribution, and the identification of a high expression gene is performed with a population having no fetal cell distribution.
7. The method of claim 1, wherein the identification of the S4 high-expression gene specifically comprises the steps of:
1) Finding high expression genes in a group (Cluster) without fetal cell distribution by using FindAllMarker;
2) Screening high-expression genes of a group (Cluster) without fetal cell distribution, and setting filtering and screening conditions;
3) Cell identification was performed on highly expressed genes of a Cluster (Cluster) without fetal cell distribution using the CellMarker database.
8. The method of claim 1, wherein the specific step of S5 annotating the amniotic fluid cells with organ sources and germ layer sources is: based on organ origin, germ layer origin was determined.
9. Use of the method according to any one of claims 1-7 for identifying and tracing cell types of primary cells in amniotic fluid samples, said use being for non-diagnostic and therapeutic purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311398690.6A CN117126949B (en) | 2023-10-26 | 2023-10-26 | Cell type and traceability method for identifying primary cells in amniotic fluid sample |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311398690.6A CN117126949B (en) | 2023-10-26 | 2023-10-26 | Cell type and traceability method for identifying primary cells in amniotic fluid sample |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117126949A true CN117126949A (en) | 2023-11-28 |
| CN117126949B CN117126949B (en) | 2024-05-03 |
Family
ID=88863166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311398690.6A Active CN117126949B (en) | 2023-10-26 | 2023-10-26 | Cell type and traceability method for identifying primary cells in amniotic fluid sample |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117126949B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112481195A (en) * | 2020-06-09 | 2021-03-12 | 首都医科大学附属北京朝阳医院 | Pulmonary artery tissue single cell suspension and preparation method and application thereof |
| CN113025567A (en) * | 2021-03-31 | 2021-06-25 | 中国人民解放军陆军特色医学中心 | Separation method of intervertebral disc single cells |
| CN114616467A (en) * | 2019-10-03 | 2022-06-10 | 瑞泽恩制药公司 | High throughput method for screening homologous T cell and epitope reactivity in primary human cells |
| CN114752688A (en) * | 2022-04-28 | 2022-07-15 | 北京大学口腔医学院 | Method, probe and kit for identifying human embryonic bone marrow-derived mesenchymal stem cells and application thereof |
-
2023
- 2023-10-26 CN CN202311398690.6A patent/CN117126949B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114616467A (en) * | 2019-10-03 | 2022-06-10 | 瑞泽恩制药公司 | High throughput method for screening homologous T cell and epitope reactivity in primary human cells |
| CN112481195A (en) * | 2020-06-09 | 2021-03-12 | 首都医科大学附属北京朝阳医院 | Pulmonary artery tissue single cell suspension and preparation method and application thereof |
| CN113025567A (en) * | 2021-03-31 | 2021-06-25 | 中国人民解放军陆军特色医学中心 | Separation method of intervertebral disc single cells |
| CN114752688A (en) * | 2022-04-28 | 2022-07-15 | 北京大学口腔医学院 | Method, probe and kit for identifying human embryonic bone marrow-derived mesenchymal stem cells and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| ATHANASIA DASARGYRI等: "scRNA-Seq of Cultured Human Amniotic Fluid from Fetuses with Spina Bifida Reveals the Origin and Heterogeneity of the Cellular Content", 《CELLS》, vol. 12, no. 1577, pages 1 - 23 * |
| JING WANG等: "Single-Cell Transcriptomics of Cultured Amniotic Fluid Cells Reveals Complex Gene Expression Alterations in Human Fetuses With Trisomy 18", 《FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY》, vol. 10, pages 1 - 13 * |
| 张卓然: "《实用细胞培养技术》", 人民卫生出版社, pages: 217 - 220 * |
| 郑玉婷等: "基于单细胞RNA 测序的人羊水间充质干细胞异质性分析", 《郑州大学学报》, vol. 57, no. 4, pages 455 - 461 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117126949B (en) | 2024-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ordovas-Montanes et al. | Allergic inflammatory memory in human respiratory epithelial progenitor cells | |
| Phipson et al. | Evaluation of variability in human kidney organoids | |
| Hasel et al. | Neuroinflammatory astrocyte subtypes in the mouse brain | |
| Melms et al. | A molecular single-cell lung atlas of lethal COVID-19 | |
| Mo et al. | Epigenomic landscapes of retinal rods and cones | |
| Aguila et al. | Oocyte selection for in vitro embryo production in bovine species: noninvasive approaches for new challenges of oocyte competence | |
| Cheong et al. | Epigenetic memory of coronavirus infection in innate immune cells and their progenitors | |
| Twigger et al. | Transcriptional changes in the mammary gland during lactation revealed by single cell sequencing of cells from human milk | |
| Xiong et al. | Single-cell RNA sequencing reveals B cell–related molecular biomarkers for Alzheimer’s disease | |
| Fadl et al. | An optimized protocol for retina single-cell RNA sequencing | |
| Barbitoff et al. | A data-driven review of the genetic factors of pregnancy complications | |
| Zhao et al. | MiRNA profiling of plasma-derived exosomes from dairy cows during gestation | |
| Qu et al. | FAM171B as a novel biomarker mediates tissue immune microenvironment in pulmonary arterial hypertension | |
| Prameela Bharathan et al. | Characterization and staging of outer plexiform layer development in human retina and retinal organoids | |
| CN117126949B (en) | Cell type and traceability method for identifying primary cells in amniotic fluid sample | |
| Zhao et al. | Co-expression network analysis of Down's syndrome based on microarray data | |
| Bellon et al. | Optimization of neurite tracing and further characterization of human monocyte-derived-neuronal-like cells | |
| Leisinger et al. | Effect of microfluidic sperm separation vs. standard sperm washing processes on laboratory outcomes and clinical pregnancy rates in an unselected patient population | |
| CN108410799A (en) | A kind of method and application thereof of isolating fetal trophocyte | |
| Naydenov et al. | Current Status and Prospects of the Single-Cell Sequencing Technologies for Revealing the Pathogenesis of Pregnancy-Associated Disorders | |
| Shannon et al. | Single-cell assessment of trophoblast stem cell-based organoids as human placenta-modeling platforms | |
| Berryer et al. | Robust induction of functional astrocytes using NGN2 expression in human pluripotent stem cells | |
| CN113035279A (en) | Parkinson disease evolution key module identification method based on miRNA sequencing data | |
| Chamberlain et al. | Methodology for Isolation of miRNA From the Serum of Women Investigated for Pre-eclampsia | |
| CN117512105B (en) | Application of marker in diagnosis of hormonal necrosis of femoral head phlegm, blood stasis and deficiency syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |